Barclays keeps Overweight on BeOne Medicines, Five9 and FIGS
Barclays maintained its Overweight rating on BeOne Medicines and Five9, and raised its FIGS price target to $28. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Barclays analysts kept an Overweight rating on BeOne Medicines (ONC), according to a notice published on November 6, 2026 at 16:14 UTC. On Five9 (FIVN) the bank also held Overweight, but lowered its price target to $38 per share from $40.
For FIGS, the Overweight rating was maintained and the price target was raised to $28 from $24. The information comes from Dow Jones Newswires, citing data from Benzinga.
why it matters
Rating updates like these concern individual stocks and usually do not move the broader market. They show one brokerage's view on each company, but they do not replace independent analysis of earnings and business prospects.
tags
instruments
sources
- BeOne Medicines Is Maintained at Overweight by Barclays — Dow Jones Newswires, 6 November 2026 at 16:14 UTC
- Five9 Is Maintained at Overweight by Barclays — Dow Jones Newswires, 6 November 2026 at 16:22 UTC
- FIGS Is Maintained at Overweight by Barclays — Dow Jones Newswires, 6 November 2026 at 16:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗